Healthcare

Bryan, Garnier & Co acts as Sole Financial Advisor to Physidia and its shareholders, a leading European renal care medtech company providing home haemodialysis solutions, on the sale of a majority stake to Columna Capital

Physidia SAS is a French medtech company pioneering a best-in-class platform for short and frequent, daily home-based haemodialysis.

The company offers the simplest, smallest, most versatile and clinically superior daily haemodialysis solution for the homecare space. It has completed close to 1,000,000 dialysis cycles since its CE approval in 2013, through selling its dialysis solution in EMEA, and has established a leading market position in Western Europe.

Bryan, Garnier & Co acts as Sole Financial Advisor to Physidia and its shareholders on the sale of a majority stake to Columna Capital.

Bryan, Garnier & Co ran a competitive M&A process introducing and guiding a range of strategics and healthcare specialists capable of understanding the home-dialysis sector. As a result, Physidia selected Columna Capital as the best partner to accelerate its international expansion and establish the company as a global leader in the sector.

This transaction is a testimony of Bryan, Garnier & Co’s expertise in supporting innovative medtech companies at critical junctures in their growth journey. It confirms the bank’s positioning as a leading advisor for mid-cap growth healthcare companies across Europe.

"We are grateful to Bryan Garnier's team commitment in helping us find the best partner for our growth journey while ensuring a strong alignment of all parties throughout the process. As our new majority shareholder, Columna will accelerate Physidia’s international expansion and bring us closer to fulfilling our ultimate mission of providing dialysis patients worldwide with flexibility, freedom, and better quality of life."

— Didier Candelot - CEO of Physidia

Physidia is a French MedTech company developing, manufacturing and commercialising innovative mobile home dialysis solutions. Founded in 2010, Physidia received the CE mark in 2013 and rapidly grew to become the leading player in the home haemodialysis market in the EU. The current version of the dialysis monitor is commercialized across 16 markets in EMEA through established distribution agreements or direct. Physidia is particularly focused on leveraging technology and innovation in order to improve the quality of life for dialysis patients.

Columna Capital is an entrepreneurial investment firm focusing on growth investments in Western Europe. The Columna team consists of an engaged group of professionals that actively support ambitious management teams and entrepreneurs to drive organic growth and execute on consolidation opportunities. Typically, Columna invests in companies with up to €100 million in revenue and significant growth potential. It has specific expertise in healthcare, services and the agri/food industries. Columna was founded in 2009 and operates from offices in London, Lugano and Luxembourg.